


PHARMACEUTICAL 2021

REVANCE°

Revance Therapeutics Inc. Rank 209 of 409





PHARMACEUTICAL 2021

REVANCE

Revance Therapeutics Inc. Rank 209 of 409

The relative strengths and weaknesses of Revance Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Revance Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 72% points. The greatest weakness of Revance Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 42% points.

The company's Economic Capital Ratio, given in the ranking table, is -138%, being 217% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	450,003
Cost of Goods Sold	0
Intangible Assets	218,307
Liabilities, Current	60,964
Liabilities, Non-Current	104,440
Other Assets	34,411
Other Compr. Net Income	-3.0
Other Expenses	23,374
Other Liabilities	180,526
Other Net Income	3,601
Property and Equipment	17,499
Research and Development	125,795
Revenues	15,325
Selling, General and Administrative Expense	151,846

Output Variable	Value in 1000 USD
Assets	720,220
Liabilities	345,930
Expenses	301,015
Stockholders Equity	374,290
Net Income	-282,089
Comprehensive Net Income	-282,090
Economic Capital Ratio	-138%